Xgeva sBLA in CRPC prevention of bone mets goes to ODAC on 2/8/12: http://finance.yahoo.com/news/FDA-Review-Potential-New-Use-prnews-188371775.html?x=0 For those keeping score, this is the indication in the fourth row of the table in #msg-57938233. p.s. Ernie Werner (an EXEL bull) has proclaimed that Xgeva is DoA in this indication. Let’s see what ODAC thinks.